TY - JOUR
T1 - Novel radioligands for imaging sigma-1 receptor in brain using positron emission tomography (PET)
AU - Lan, Yu
AU - Bai, Ping
AU - Chen, Zude
AU - Neelamegam, Ramesh
AU - Placzek, Michael S.
AU - Wang, Hao
AU - Fiedler, Stephanie A.
AU - Yang, Jing
AU - Yuan, Gengyang
AU - Qu, Xiying
AU - Schmidt, Hayden R.
AU - Song, Jinchun
AU - Normandin, Marc D.
AU - Ran, Chongzhao
AU - Wang, Changning
N1 - Funding Information:
This work was supported by a pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (Changning Wang, USA), National Natural Science Foundation of China (Grant No. 81602946 , Yu Lan) and Natural Science Foundation of Hubei Provinc e of China (Grant No. 2016CFB258 , Yu Lan). The authors are grateful to Prof. Andrew C. Kruse in Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School for the constructive discussion and enthusiastic help in molecular docking, the Athinoula A. Martinos Center Radiopharmacy Lab staff for assistant in radiochemistry and Prof. Xudong Cao in Xuzhou Medical School for the discussion in chemistry and structure identification.
Funding Information:
This work was supported by a pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (Changning Wang, USA), National Natural Science Foundation of China (Grant No.81602946, Yu Lan) and Natural Science Foundation of Hubei Province of China (Grant No. 2016CFB258, Yu Lan). The authors are grateful to Prof. Andrew C. Kruse in Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School for the constructive discussion and enthusiastic help in molecular docking, the Athinoula A. Martinos Center Radiopharmacy Lab staff for assistant in radiochemistry and Prof. Xudong Cao in Xuzhou Medical School for the discussion in chemistry and structure identification.
Publisher Copyright:
© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
PY - 2019/11
Y1 - 2019/11
N2 - The sigma-1 receptor (σ1R) is a unique intracellular protein. σ1R plays a major role in various pathological conditions in the central nervous system (CNS), implicated in several neuropsychiatric disorders. Imaging of σ1R in the brain using positron emission tomography (PET) could serve as a noninvasively tool for enhancing the understanding of the disease's pathophysiology. Moreover, σ1R PET tracers can be used for target validation and quantification in diagnosis. Herein, we describe the radiosynthesis, in vivo PET/CT imaging of novel σ1R 11C-labeled radioligands based on 6-hydroxypyridazinone, [11C]HCC0923 and [11C]HCC0929. Two radioligands have high affinities to σ1R, with good selectivity. In mice PET/CT imaging, both radioligands showed appropriate kinetics and distributions. Additionally, the specific interactions of two radioligands were reduced by compounds 13 and 15 (self-blocking). Of the two, [11C]HCC0929 was further investigated in positive ligands blocking studies, using classic σ1R agonist SA 4503 and σ1R antagonist PD 144418. Both σ1R ligands could extensively decreased the uptake of [11C]HCC0929 in mice brain. Besides, the biodistribution of major brain regions and organs of mice were determined in vivo. These studies demonstrated that two radioligands, especially [11C]HCC0929, possessed ideal imaging properties and might be valuable tools for non-invasive quantification of σ1R in brain.
AB - The sigma-1 receptor (σ1R) is a unique intracellular protein. σ1R plays a major role in various pathological conditions in the central nervous system (CNS), implicated in several neuropsychiatric disorders. Imaging of σ1R in the brain using positron emission tomography (PET) could serve as a noninvasively tool for enhancing the understanding of the disease's pathophysiology. Moreover, σ1R PET tracers can be used for target validation and quantification in diagnosis. Herein, we describe the radiosynthesis, in vivo PET/CT imaging of novel σ1R 11C-labeled radioligands based on 6-hydroxypyridazinone, [11C]HCC0923 and [11C]HCC0929. Two radioligands have high affinities to σ1R, with good selectivity. In mice PET/CT imaging, both radioligands showed appropriate kinetics and distributions. Additionally, the specific interactions of two radioligands were reduced by compounds 13 and 15 (self-blocking). Of the two, [11C]HCC0929 was further investigated in positive ligands blocking studies, using classic σ1R agonist SA 4503 and σ1R antagonist PD 144418. Both σ1R ligands could extensively decreased the uptake of [11C]HCC0929 in mice brain. Besides, the biodistribution of major brain regions and organs of mice were determined in vivo. These studies demonstrated that two radioligands, especially [11C]HCC0929, possessed ideal imaging properties and might be valuable tools for non-invasive quantification of σ1R in brain.
KW - 6-Hydroxypyridazinone
KW - Brain imaging
KW - C-labeled radioligand
KW - PET
KW - σR
UR - http://www.scopus.com/inward/record.url?scp=85075804623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075804623&partnerID=8YFLogxK
U2 - 10.1016/j.apsb.2019.07.002
DO - 10.1016/j.apsb.2019.07.002
M3 - Article
AN - SCOPUS:85075804623
SN - 2211-3835
VL - 9
SP - 1204
EP - 1215
JO - Acta Pharmaceutica Sinica B
JF - Acta Pharmaceutica Sinica B
IS - 6
ER -